354 related articles for article (PubMed ID: 29752262)
1. CD4
Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
[TBL] [Abstract][Full Text] [Related]
6. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.
Schüler T; Blankenstein T
J Immunol; 2003 May; 170(9):4427-31. PubMed ID: 12707316
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Tveita A; Fauskanger M; Bogen B; Haabeth OA
Oncotarget; 2016 Oct; 7(41):67175-67182. PubMed ID: 27626487
[TBL] [Abstract][Full Text] [Related]
8. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
9. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
Kahn M; Sugawara H; McGowan P; Okuno K; Nagoya S; Hellström KE; Hellström I; Greenberg P
J Immunol; 1991 May; 146(9):3235-41. PubMed ID: 1707934
[TBL] [Abstract][Full Text] [Related]
11. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
[TBL] [Abstract][Full Text] [Related]
12. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.
Pietra BA; Wiseman A; Bolwerk A; Rizeq M; Gill RG
J Clin Invest; 2000 Oct; 106(8):1003-10. PubMed ID: 11032860
[TBL] [Abstract][Full Text] [Related]
14. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
15. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
16. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
17. Direct recognition of rat MHC antigens on rat antigen-presenting cells by mouse CD4+ and CD8+ T cells and establishment of T cell clones exhibiting a direct recognition pathway.
Hirota T; Hirose H; Iwata H; Kanetake K; Murakawa S; Sasaki E; Takagi H; Bando M; Hamaoka T; Fujiwara H
Transplantation; 1997 Mar; 63(5):705-10. PubMed ID: 9075842
[TBL] [Abstract][Full Text] [Related]
18. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis.
Turley DM; Miller SD
J Immunol; 2007 Feb; 178(4):2212-20. PubMed ID: 17277126
[TBL] [Abstract][Full Text] [Related]
19. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
20. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
